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A first-derivative spectrophotometric method for the
simultaneous determination of piroxicam (PX) and its
major metabolite 5A-hydroxypiroxicam (OH PX) in human
plasma is described. The method consists of direct
extraction of the two drugs from the plasma samples with
hydrochloric and trichloroacetic acid prior to their
determination by measuring the first-derivative signals at
337.0 nm for PX and at 327.0 nm for OHPX
(zero-crossing wavelength). The calibration graphs were
linear up to 10.0 and 8.0 mg l21 of PX and OH PX,
respectively, and the limits of quantification were 0.27 and
0.56 mg l21. The possible interfering effects of other
substances were studied.
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Piroxicam, 4-hydroxy-2-methyl-N-(2-pyridyl)-2-H-1,2-benzo-
thiazine-3-carboxamide 1,1-dioxide (PX), is a non-steroidal
anti-inflammatory drug (NSAID) belonging to a class of
compounds called oxicams.1 Its anti-inflammatory action is
caused by its inhibition of prostaglandin synthetase, and it is the
most widely used drug in the treatment of patients suffering
from rheumatological disoders. It may be administered system-
atically or topically and its once-daily administration has made
it widely appreciated when NSAID treatment is required for a
chronic condition.
It has been suggested2 that PX is completely absorbed after
both oral and rectal administration, peak plasma concentration
(Cmax) being achieved 2–3 h after a single oral dose and 5–6 h
after a single rectal dose. Mean peak plasma concentrations are
roughly related to dosage, being 1.5–3 and 6–8 mg l21 after a
single 20 or 60 mg dose, respectively. Because of the long t1/2b
(terminal elimination half-life), once-daily administration keeps
the plasma PX concentration relatively stable. The main
metabolic pathway of PX involves the hydroxylation of the
5-pyridine ring, resulting in 5A-hydroxypiroxicam (OHPX) as
oxidation product. This metabolite is less active than the drug
itself in inhibiting prostaglandin biosynthesis.
The pharmacology and pharmacokinetic and clinical efficacy
of PX have recently been reviewed.2 In the earliest studies of
PX in humans, plasma levels were measured by spectrophoto-
metric or fluorimetric techniques,3–5 although such methods
lacked selectivity and sensitivity. Since then, several chromato-
graphic methods have been reported for the determination of PX
in biological fluids.6–14 However, most of these methods, while
providing a high degree of sensitivity, are complicated and time
consuming, which led us to search for a simple, rapid, reliable
and specific method for the determination of PX and its major
metabolite OHPX in human plasma. The classical UV/VIS
spectrophotometric method presents the severe problem of
overlapping spectral bands of PX, OHPX and the plasma
background, which makes the simultaneous determination of
these drugs impossible in this matrix.
This paper describes the application of derivative UV/VIS
spectrophotometry to the simultaneous determination of PX and
its metabolite OHPX in human plasma. This technique, which
involves calculating and plotting one of the mathematical
derivatives of a spectral curve, offers an alternative approach to
drug analysis and shows greatest sensitivity and specificity.
Although the derivative transformation does not increase the
information content of a spectrum, it does permit discrimination
against broad band interferences which arise from turbidity or
non-specific matrix absorption. It also emphasizes subtle
spectral features of the data by presenting them in a new and
visually more accessible way. Several papers on the theoretical
aspects of derivative spectrophotometry have been pub-
lished.15–19 The recognized resolution enhancement of deriva-
tive UV/VIS spectrophotometry has been used advantageously




A Shimadzu (Kyoto, Japan) UV 240 double-beam spec-
trophotometer with an optional program unit (Model OPI-2) and
1 cm quartz cell was used. The most suitable settings were slit
width 2 nm (the response time was automatically adjusted
according to the slit width), scan speed 45 nm min21 and
derivative wavelength difference 4 nm. The recorder scale
expansion was optimized to facilitate readings on the recorder
trace.
Standard solutions and sample preparation
All chemicals and solvents were of analytical-reagent grade and
solutions were prepared with doubly distilled water.
Piroxicam and 5A-hydroxypiroxicam stock standard solutions
(400.0 mg l21) were prepared by dissolving 40.0 mg of PX
(Sigma, St. Louis, MO, USA) or OHPX (kindly provided by
Lab. Pfizer, Madrid, Spain) in 100 ml of methanol A series of
working standard solutions containing equal amounts of PX and
OHPX between 15.0 and 150.0 mg l21 were prepared by
appropriate dilution with saline solution of the stock standard
solutions.
Plasma samples simultaneously spiked with PX and OHPX
were prepared by diluting 0.2 ml aliquots of working standard
solutions in a 1.8 ml serum pool. The final concentration of both
PX and OHPX in the plasma standard were 1–10 mg l21.
Triglycerides were supplemented with Intralipid (Pharmacia
and Upjohn, Madrid, Spain). Hemoglobin and bilirubin were
purchased from Sigma.
Calibration procedure
Aliquots of 0.2 ml of the working standard solution were placed
in 10 ml centrifuge tubes and 1.8 ml of human plasma was
added. The spiked plasma samples were acidified with 1.0 ml of
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1.0 m HCl. After 15 min, 1.0 ml of 20% trichloroacetic acid was
added. The mixture was shaken for 1 min and centrifuged at
3500 rev min21 (2270g) for 10 min. The aqueous layer was
separated and the first-order derivative spectrum of this solution
was recorded over the wavelength range of 310–400 nm. The




Fig. 1 shows the zero-order absorption spectra of blank plasma
taken from one individual (A), blank plasma spiked with 2.5
mg l21 5A-hydroxypiroxicam (B) or piroxicam (C), or both
mixed in a 1 : 1 ratio (D). PX exhibits an absorbance maximum
at 333 nm and OHPX at 340 nm; the blank plasma has a very
low absorbance at these wavelengths. Similar spectra were
obtained when the same procedure was repeated with individual
plasma samples taken from 10 volunteers. There is a clear
overlapping of the spectra, which prevents the simultaneous
determination of the compounds by direct UV/VIS absorbance
measurements in plasma.
Derivative spectrophotometry is a suitable technique for
overcoming this problem, with the zero-crossing method being
the most common procedure for the preparation of calibration
graphs. In practice, the measurements selected are those which
exhibit the best linear response, give a zero or near zero
intercept on the ordinate of the calibration graphs and are least
affected by the concentration of any other component.
Fig. 2 shows the first-derivative UV/VIS spectra of the same
solutions as in Fig. 1. Derivatization of the zero-order spectra
leads to an improvement of the spectral details and the resulting
first-derivative spectra present spectral features which can be
used for the simultaneous determination of PX and OHPX.
Owing to the overlapping spectra, the zero-crossing method is
clearly the most appropriate approach for resolving mixtures of
these compounds and it was used in this work with satisfactory
results. Preliminary experiments with 10 different blank plasma
samples and one taken from a serum pool showed that the first-
derivative signals at 337.0 nm (working blank plasma zero-
crossing wavelength of OHPX) are proportional to the PX
concentration and the first-derivative signals at 327.0 nm
(working blank plasma zero-crossing wavelength of PX) are
proportional to the OHPX concentration.
Selection of optimum instrumental conditions
The main instrumental parameters that affect the shape of the
derivative spectra are the wavelength scanning speed, the
Fig 1 Absorption (zero-order) spectra of (A) blank plasma, (B) blank plasma
spiked with 2.5 mg l21 of OHPX, (C) blank plasma spiked with 2.5 mg l21
of PX and (D) blank plasma spiked with 2.5 mg l21 of PX and 2.5 mg l21
of OHPX.
Fig. 2 First-derivative spectra (Dl = 4 nm) of (A) blank plasma, (B) blank
plasma spiked with 2.5 mg l21 of OHPX, (C) blank plasma spiked with 2.5
mg l21 of PX and (D) blank plasma spiked with 2.5 mg l21 of PX and 2.5
mg l21 of OHPX.
Table 1 Calibration data for the simultaneous determination of PX and
OHPX in plasma
Compound Equation r
PX 1D337 = 1.50 3 1023 (± 2.19 31024)*
+ 6.04 3 1023 (± 3.9 3 1025) [PX]† 0.9998
OHPX 1D327 = 23.14 3 1023 (± 1.60 3 1024)*
+ 3.31 3 1023 (± 3.9 3 1025) [OHPX]† 0.9994
* ± s; n = 12. † Concentration in mg l21.
Fig 3 First-derivative spectra (Dl = 4 nm) of plasma samples containing
(A) different concentrations of OHPX [(1) 0.0; (2) 2.5; (3) 5.0 mg l21] and
2.5 mg l21 of PX and (B) different concentrations of PX [(1) 0.0; (2) 2.5; (3)
5.0 mg l21] and 2.5 mg l21 of OHPX.
1750 Analyst, August 1998, Vol. 123
wavelength increment over which the derivative is obtained
(Dl) and the smoothing, all of which need to be optimized to
give a well resolved, large peak. Generally, the noise level
decreases with increase in Dl, which leads to less pronounced
fluctuations in the derivative spectrum. Since the spectral
resolution is very poor at excessively high Dl values, the
optimum value of Dl should be determined by taking into
account the noise level, the resolution of the spectrum and the
sample concentration. Several values of Dl were tested and 4.0
nm was selected as the optimum for a satisfactory signal-to-
noise ratio.
After establishing the optimum experimental conditions, the
first-derivative spectra of two series of plasma samples
containing various concentrations of OHPX (0.0, 2.5 and 5.0
mg l21) and a constant concentration of PX (2.5 mg l21) or
various concentrations of PX (0.0, 2.5 and 5.0 mg l21) and a
constant concentration of OHPX (2.5 mg l21) were constructed
in order to investigate the effect of PX and OHPX on the
simultaneous determination of the two compounds in plasma
samples. Fig. 3 shows that the heights (h1 and h2) were not
affected by the presence of OHPX or PX over the range of
concentration studied in the first-derivative mode.
Determination of PX and OHPX in human plasma
Some binary mixtures of PX and OHPX in the plasma samples
were prepared from the working standard solution in the
proportions 1 + 1, using the recommended procedure. The first-
order derivative spectra of these sample were recorded over the
wavelength range 310–400 nm against a blank consisting of
saline solution. The calibration graphs were constructed by
plotting the analytical signals 1DPX at 337.0 nm and 1DOHPX at
327.0 nm versus the PX or OHPX concentration (mg l21). The
ordinate values 1D of the equations were calculated from the
amplitude measurements (mm) and standardized as follows: 1D
= recorder divisions (h mm) 3 scale expansion /150 mm full-
scale.31 Table 1 summarizes the statistical data obtained from
two calibration graphs. Linear relationships were obtained for
concentrations up to 10.0 and 8.0 mg l21 of PX and OHPX,
respectively.
The reproducibility of the endogenous background signal was
evaluated from 10 different individual blank plasma samples.
The values obtained were 1.38 3 1023 ± 1.67 3 1024 and 1.90
3 1023 ± 1.85 3 1024 (mean of analytical signal ± standard
deviation) at 337.0 and 327.0 nm, respectively.
The detection and quantification limits achieved, as defined
by IUPAC,32 were 0.083 and 0.27 mg l21 for PX and 0.16 and
0.56 mg l21 for OHPX.
We demonstrated that the method permits the simultaneous
determination of 0.40 mg l21 of PX in the presence of up to 8.0
mg l21 of OHPX and 0.66 mg l21 of OHPX in the presence of
up to 10.0 mg l21 of PX.
The precision of the method was evaluated by analysing 10
replicate plasma samples obtained from different individuals
spiked with 5.0 mg l21 of each compound. The RSDs obtained
were 2.01 and 2.18% for PX and OHPX, respectively.
Bilirubin, triglycerides and hemoglobin were tested for
possible interference effects in the simultaneous determination
of 5.0 mg l21 of PX and OHPX. No interference was observed
even when bilirubin was present at a concentration of 100
mg l21, triglycerides at 10 g l21 and hemoglobin at 2.5 g l21.
In addition to the anti-inflammatory drug PX, some patients
may be given other drugs to alleviate pain and other symptoms
of arthritis. In the physiological concentration range obtained
after the usual therapeutic doses of the drugs had been
administered, no interference was observed from penicillamine,
prednisolone, ranitidine, misoprostol and sodium aurothioma-
late, but chloroquine and azathioprine did interfere.
The validity of the proposed method was confirmed by
applying the standard additions technique to different blank
plasma samples. The results are given in Table 2. Quantitative
recoveries of 95.6–106 and 95.0–107.6% were obtained for PX
and OHPX, respectively.
Conclusions
The proposed first-derivative UV/VIS spectrophotometric
method is suitable for the simultaneous determination of
piroxicam and its major metabolite 5A-hydroxypiroxicam in
human plasma. It is a simple and precise procedure which
requires inexpensive reagents and which can be used for rapid
and reliable clinical and pharmacokinetic studies of PX and
OHPX simultaneously.
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